GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Inventories, Other
Switch to:

Biogen (BUE:BIIB) Inventories, Other

: ARS-8,337 Mil (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Biogen's other inventories for the quarter that ended in Mar. 2023 was ARS-8,337 Mil.

Biogen's quarterly other inventories declined from Sep. 2022 (ARS0 Mil) to Dec. 2022 (ARS-3,537 Mil) and declined from Dec. 2022 (ARS-3,537 Mil) to Mar. 2023 (ARS-8,337 Mil).

Biogen's annual other inventories declined from Dec. 2020 (ARS0 Mil) to Dec. 2021 (ARS0 Mil) and declined from Dec. 2021 (ARS0 Mil) to Dec. 2022 (ARS-3,537 Mil).


Biogen Inventories, Other Historical Data

The historical data trend for Biogen's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Inventories, Other
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35,061.88 - - - -3,537.42

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Inventories, Other Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -3,537.42 -8,336.61

Biogen Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines